Skip to main content
SpringerLink
Log in

The Increased Risk of Cancer in Obesity and Type 2 Diabetes: Potential Mechanisms

  • Living reference work entry
  • Latest version View entry history
  • First Online:
Principles of Diabetes Mellitus

  • 203 Accesses

Abstract

Theories on a connection between diabetes, obesity, and cancer have existed for over a century. In 1910, despite their elusive etiologies, Maynard hypothesized that a correlation between diabetes and cancer could exist, as both conditions were increasing in prevalence and had similar age distributions. In this chapter, we review the epidemiology linking obesity, diabetes, and cancer incidence and mortality and discuss some of the physiological changes that occur in obesity and type 2 diabetes that may contribute to cancer growth and metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

References

  1. Maynard GD. A statistical study in cancer death-rates. Biometrika 1910;7(3):276–304. doi:10.1093/biomet/7.3.276.

    Google Scholar 

  2. Kessler II. Cancer and diabetes mellitus. A review of the literature. J Chronic Dis. 1971;23(8):579–600.

    Article  CAS  PubMed  Google Scholar 

  3. Sell C. Caloric restriction and insulin-like growth factors in aging and cancer. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2003;35(11–12):705–11. doi:10.1055/s-2004-814156.

    Google Scholar 

  4. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38. doi:10.1056/NEJMoa021423.

    Article  PubMed  Google Scholar 

  5. Campbell PT, Newton CC, Patel AV, Jacobs EJ, Gapstur SM. Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults. Diabetes Care. 2012;35(9):1835–44. doi:10.2337/dc12-0002.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Hjalgrim H, Frisch M, Ekbom A, Kyvik KO, Melbye M, Green A. Cancer and diabetes – a follow-up study of two population-based cohorts of diabetic patients. J Intern Med. 1997;241(6):471–5.

    Article  CAS  PubMed  Google Scholar 

  7. Stattin P, Bjor O, Ferrari P, Lukanova A, Lenner P, Lindahl B, et al. Prospective study of hyperglycemia and cancer risk. Diabetes Care. 2007;30(3):561–7. doi:10.2337/dc06-0922.

    Article  PubMed  Google Scholar 

  8. Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005;293(2):194–202. doi:10.1001/jama.293.2.194.

    Article  CAS  PubMed  Google Scholar 

  9. Verlato G, Zoppini G, Bonora E, Muggeo M. Mortality from site-specific malignancies in type 2 diabetic patients from Verona. Diabetes Care. 2003;26(4):1047–51.

    Article  PubMed  Google Scholar 

  10. Handelsman Y, Leroith D, Bloomgarden ZT, Dagogo-Jack S, Einhorn D, Garber AJ, et al. Diabetes and cancer – an AACE/ACE consensus statement. Endocr Pract. 2013;19(4):675–93. doi:10.4158/EP13248.CS.

    Article  PubMed  Google Scholar 

  11. Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674–85. doi:10.2337/dc10-0666.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbjornsdottir S, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373(18):1720–32. doi:10.1056/NEJMoa1504347.

    Article  CAS  PubMed  Google Scholar 

  13. Harding JL, Shaw JE, Peeters A, Cartensen B, Magliano DJ. Cancer risk among people with type 1 and type 2 diabetes: disentangling true associations, detection bias, and reverse causation. Diabetes Care. 2015;38(2):264–70. doi:10.2337/dc14-1996.

    Article  PubMed  Google Scholar 

  14. Hsu PC, Lin WH, Kuo TH, Lee HM, Kuo C, Li CY. A population-based cohort study of all-cause and site-specific cancer incidence among patients with type 1 diabetes mellitus in Taiwan. J Epidemiol/Jpn Epidemiol Assoc. 2015;25(9):567–73. doi:10.2188/jea.JE20140197.

    Article  Google Scholar 

  15. Zendehdel K, Nyren O, Ostenson CG, Adami HO, Ekbom A, Ye W. Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst. 2003;95(23):1797–800.

    Article  PubMed  Google Scholar 

  16. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311(8):806–14. doi:10.1001/jama.2014.732.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9945):766–81. doi:10.1016/S0140-6736(14)60460-8.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5. doi:10.1161/CIRCULATIONAHA.109.192644.

    Article  CAS  PubMed  Google Scholar 

  19. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569–78. doi:10.1016/S0140-6736(08)60269-X.

    Article  PubMed  Google Scholar 

  20. Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, et al. Clinical cancer advances 2015: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015;33(7):786–809. doi:10.1200/JCO.2014.59.9746.

    Article  PubMed  Google Scholar 

  21. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath Jr CW. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 1999;341(15):1097–105. doi:10.1056/NEJM199910073411501.

    Article  CAS  PubMed  Google Scholar 

  22. Gaudet MM, Carter BD, Patel AV, Teras LR, Jacobs EJ, Gapstur SM. Waist circumference, body mass index, and postmenopausal breast cancer incidence in the cancer prevention study-II nutrition cohort. Cancer Causes Control. 2014;25(6):737–45. doi:10.1007/s10552-014-0376-4.

    Article  PubMed  Google Scholar 

  23. Harvie M, Hooper L, Howell AH. Central obesity and breast cancer risk: a systematic review. Obes Rev. 2003;4(3):157–73.

    Article  CAS  PubMed  Google Scholar 

  24. Moghaddam AA, Woodward M, Huxley R. Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70,000 events. Cancer Epidemiol Biomarkers Prev. 2007;16(12):2533–47. doi:10.1158/1055-9965.EPI-07-0708.

    Article  PubMed  Google Scholar 

  25. Sjostrom L, Gummesson A, Sjostrom CD, Narbro K, Peltonen M, Wedel H, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 2009;10(7):653–62. doi:10.1016/S1470-2045(09)70159-7.

    Article  PubMed  Google Scholar 

  26. Adams TD, Stroup AM, Gress RE, Adams KF, Calle EE, Smith SC, et al. Cancer incidence and mortality after gastric bypass surgery. Obesity. 2009;17(4):796–802. doi:10.1038/oby.2008.610.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, Colditz GA, et al. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses’ Health Study. Diabetes Care. 2003;26(6):1752–8.

    Article  PubMed  Google Scholar 

  28. Davis AA, Kaklamani VG. Metabolic syndrome and triple-negative breast cancer: a new paradigm. Int J Breast Cancer. 2012;2012:809291. doi:10.1155/2012/809291.

    Article  PubMed  Google Scholar 

  29. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer. 2007;121(4):856–62. doi:10.1002/ijc.22717.

    Article  CAS  PubMed  Google Scholar 

  30. Petrelli JM, Calle EE, Rodriguez C, Thun MJ. Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. Cancer Causes Control. 2002;13(4):325–32.

    Article  PubMed  Google Scholar 

  31. Aune D, Navarro Rosenblatt DA, Chan DS, Vingeliene S, Abar L, Vieira AR, et al. Anthropometric factors and endometrial cancer risk: a systematic review and dose–response meta-analysis of prospective studies. Ann Oncol/ESMO. 2015;26(8):1635–48. doi:10.1093/annonc/mdv142.

    Article  CAS  Google Scholar 

  32. Crosbie EJ, Zwahlen M, Kitchener HC, Egger M, Renehan AG. Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev. 2010;19(12):3119–30. doi:10.1158/1055-9965.EPI-10-0832.

    Article  CAS  Google Scholar 

  33. Adams TD, Hunt SC. Cancer and obesity: effect of bariatric surgery. World J Surg. 2009;33(10):2028–33. doi:10.1007/s00268-009-0169-1.

    Article  PubMed  Google Scholar 

  34. Saltzman BS, Doherty JA, Hill DA, Beresford SA, Voigt LF, Chen C, et al. Diabetes and endometrial cancer: an evaluation of the modifying effects of other known risk factors. Am J Epidemiol. 2008;167(5):607–14. doi:10.1093/aje/kwm333.

    Article  PubMed  Google Scholar 

  35. Olsen CM, Nagle CM, Whiteman DC, Ness R, Pearce CL, Pike MC, et al. Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocr Relat Cancer. 2013;20(2):251–62. doi:10.1530/ERC-12-0395.

    Article  PubMed  Google Scholar 

  36. Pavelka JC, Brown RS, Karlan BY, Cass I, Leuchter RS, Lagasse LD, et al. Effect of obesity on survival in epithelial ovarian cancer. Cancer. 2006;107(7):1520–4. doi:10.1002/cncr.22194.

    Article  PubMed  Google Scholar 

  37. Gapstur SM, Patel AV, Diver WR, Hildebrand JS, Gaudet MM, Jacobs EJ, et al. Type II diabetes mellitus and the incidence of epithelial ovarian cancer in the cancer prevention study-II nutrition cohort. Cancer Epidemiol Biomarkers Prev. 2012;21(11):2000–5. doi:10.1158/1055-9965.EPI-12-0867.

    Article  PubMed  Google Scholar 

  38. Shah MM, Erickson BK, Matin T, McGwin Jr G, Martin JY, Daily LB, et al. Diabetes mellitus and ovarian cancer: more complex than just increasing risk. Gynecol Oncol. 2014;135(2):273–7. doi:10.1016/j.ygyno.2014.09.004.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med. 2006;166(17):1871–7. doi:10.1001/archinte.166.17.1871.

    Article  PubMed  Google Scholar 

  40. Weiderpass E, Ye W, Vainio H, Kaaks R, Adami HO. Diabetes mellitus and ovarian cancer (Sweden). Cancer Causes Control. 2002;13(8):759–64.

    Article  PubMed  Google Scholar 

  41. Swerdlow AJ, Laing SP, Qiao Z, Slater SD, Burden AC, Botha JL, et al. Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study. Br J Cancer. 2005;92(11):2070–5. doi:10.1038/sj.bjc.6602611.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Ulmer H, Bjorge T, Concin H, Lukanova A, Manjer J, Hallmans G, et al. Metabolic risk factors and cervical cancer in the metabolic syndrome and cancer project (Me-Can). Gynecol Oncol. 2012;125(2):330–5. doi:10.1016/j.ygyno.2012.01.052.

    Article  CAS  PubMed  Google Scholar 

  43. Frumovitz M, Jhingran A, Soliman PT, Klopp AH, Schmeler KM, Eifel PJ. Morbid obesity as an independent risk factor for disease-specific mortality in women with cervical cancer. Obstet Gynecol. 2014;124(6):1098–104. doi:10.1097/AOG.0000000000000558.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO. Overweight as an avoidable cause of cancer in Europe. Int J Cancer. 2001;91(3):421–30.

    Article  CAS  PubMed  Google Scholar 

  45. Zhang X, Zhou G, Sun B, Zhao G, Liu D, Sun J, et al. Impact of obesity upon prostate cancer-associated mortality: a meta-analysis of 17 cohort studies. Oncol lett. 2015;9(3):1307–12. doi:10.3892/ol.2014.2841.

    PubMed  Google Scholar 

  46. Cai H, Xu Z, Xu T, Yu B, Zou Q. Diabetes mellitus is associated with elevated risk of mortality amongst patients with prostate cancer: a meta-analysis of 11 cohort studies. Diabetes Metab Res Rev. 2014. doi:10.1002/dmrr.2582.

    Google Scholar 

  47. Kasper JS, Giovannucci E. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2056–62. doi:10.1158/1055-9965.EPI-06-0410.

    Article  PubMed  Google Scholar 

  48. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579–91. doi:10.1038/nrc1408.

    Article  CAS  PubMed  Google Scholar 

  49. Rieken M, Xylinas E, Kluth L, Crivelli JJ, Chrystal J, Faison T, et al. Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer. BJU Int. 2013;112(8):1105–12. doi:10.1111/bju.12448.

    Article  CAS  PubMed  Google Scholar 

  50. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005;97(22):1679–87. doi:10.1093/jnci/dji375.

    Article  PubMed  Google Scholar 

  51. Hu FB, Manson JE, Liu S, Hunter D, Colditz GA, Michels KB, et al. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst. 1999;91(6):542–7.

    Article  CAS  PubMed  Google Scholar 

  52. Aleksandrova K, Boeing H, Jenab M, Bas Bueno-de-Mesquita H, Jansen E, van Duijnhoven FJ, et al. Metabolic syndrome and risks of colon and rectal cancer: the European prospective investigation into cancer and nutrition study. Cancer Prev Res. 2011;4(11):1873–83. doi:10.1158/1940-6207.CAPR-11-0218.

    Article  CAS  Google Scholar 

  53. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough RJ, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004;350(10):991–1004. doi:10.1056/NEJMoa032071.

    Article  CAS  PubMed  Google Scholar 

  54. Cronin KA, Krebs-Smith SM, Feuer EJ, Troiano RP, Ballard-Barbash R. Evaluating the impact of population changes in diet, physical activity, and weight status on population risk for colon cancer (United States). Cancer Causes control. 2001;12(4):305–16.

    Article  CAS  PubMed  Google Scholar 

  55. Jafri SH, Mills G. Lifestyle modification in colorectal cancer patients: an integrative oncology approach. Future Oncol. 2013;9(2):207–18. doi:10.2217/fon.12.184.

    Article  CAS  PubMed  Google Scholar 

  56. Devesa SS, Blot WJ, Fraumeni Jr JF. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83(10):2049–53.

    Article  CAS  PubMed  Google Scholar 

  57. Kubo A, Corley DA. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2006;15(5):872–8. doi:10.1158/1055-9965.EPI-05-0860.

    Article  PubMed  Google Scholar 

  58. Mayne ST, Navarro SA. Diet, obesity and reflux in the etiology of adenocarcinomas of the esophagus and gastric cardia in humans. J Nutr. 2002;132(11 Suppl):3467S–70S.

    CAS  PubMed  Google Scholar 

  59. Ji BT, Chow WH, Yang G, McLaughlin JK, Gao RN, Zheng W, et al. Body mass index and the risk of cancers of the gastric cardia and distal stomach in Shanghai, China. Cancer Epidemiol Biomarkers Prev. 1997;6(7):481–5.

    CAS  PubMed  Google Scholar 

  60. Dixon JL, Copeland LA, Zeber JE, MacCarthy AA, Reznik SI, Smythe WR, et al. Association between diabetes and esophageal cancer, independent of obesity, in the United States Veterans Affairs population. Dis Esophagus. 2015. doi:10.1111/dote.12402.

    PubMed  Google Scholar 

  61. Showalter SL, Rosato EL, Anne PR, Scott W, Mitchell E, Berger AC. Does diabetes mellitus influence pathologic complete response and tumor downstaging after neoadjuvant chemoradiation for esophageal and gastroesophageal cancer? A two-institution report. J Surg Oncol. 2010;101(1):43–6. doi:10.1002/jso.21418.

    Article  PubMed  Google Scholar 

  62. Bell ET. Carcinoma of the pancreas. I. A clinical and pathologic study of 609 necropsied cases. II. The relation of carcinoma of the pancreas to diabetes mellitus. Am J Pathol. 1957;33(3):499–523.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Magruder JT, Elahi D, Andersen DK. Diabetes and pancreatic cancer: chicken or egg? Pancreas. 2011;40(3):339–51. doi:10.1097/MPA.0b013e318209e05d.

    Article  PubMed  Google Scholar 

  64. Wang F, Herrington M, Larsson J, Permert J. The relationship between diabetes and pancreatic cancer. Mol Cancer. 2003;2:4.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Patel AV, Rodriguez C, Bernstein L, Chao A, Thun MJ, Calle EE. Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. Cohort. Cancer Epidemiol Biomarkers Prev. 2005;14(2):459–66. doi:10.1158/1055-9965.EPI-04-0583.

    Article  PubMed  Google Scholar 

  66. Hammerstad SS, Grock SF, Lee HJ, Hasham A, Sundaram N, Tomer Y. Diabetes and hepatitis C: a two-way association. Front Endocrinol. 2015;6:134. doi:10.3389/fendo.2015.00134.

    Article  Google Scholar 

  67. Shaib YH, El-Serag HB, Davila JA, Morgan R, McGlynn KA. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case–control study. Gastroenterology. 2005;128(3):620–6.

    Article  PubMed  Google Scholar 

  68. Larsson SC, Wolk A. Body mass index and risk of multiple myeloma: a meta-analysis. Int J Cancer. 2007;121(11):2512–6. doi:10.1002/ijc.22968.

    Article  CAS  PubMed  Google Scholar 

  69. Larsson SC, Wolk A. Obesity and risk of non-Hodgkin’s lymphoma: a meta-analysis. Int J Cancer. 2007;121(7):1564–70. doi:10.1002/ijc.22762.

    Article  CAS  PubMed  Google Scholar 

  70. Birmann BM, Giovannucci E, Rosner B, Anderson KC, Colditz GA. Body mass index, physical activity, and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev. 2007;16(7):1474–8. doi:10.1158/1055-9965.EPI-07-0143.

    Article  PubMed  Google Scholar 

  71. Khan AE, Gallo V, Linseisen J, Kaaks R, Rohrmann S, Raaschou-Nielsen O, et al. Diabetes and the risk of non-Hodgkin’s lymphoma and multiple myeloma in the European prospective investigation into cancer and nutrition. Haematologica. 2008;93(6):842–50. doi:10.3324/haematol.12297.

    Article  PubMed  Google Scholar 

  72. Wu W, Merriman K, Nabaah A, Seval N, Seval D, Lin H, et al. The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer. 2014;111(3):628–36. doi:10.1038/bjc.2014.307.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Olson JE, Yang P, Schmitz K, Vierkant RA, Cerhan JR, Sellers TA. Differential association of body mass index and fat distribution with three major histologic types of lung cancer: evidence from a cohort of older women. Am J Epidemiol. 2002;156(7):606–15.

    Article  CAS  PubMed  Google Scholar 

  74. Kuriki K, Hirose K, Tajima K. Diabetes and cancer risk for all and specific sites among Japanese men and women. Eur J Cancer Prev. 2007;16(1):83–9. doi:10.1097/01.cej.0000228404.37858.40.

    Article  PubMed  Google Scholar 

  75. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab. 2006;17(8):328–36. doi:10.1016/j.tem.2006.08.006.

    Article  CAS  PubMed  Google Scholar 

  76. LeRoith D, Roberts Jr CT. The insulin-like growth factor system and cancer. Cancer Lett. 2003;195(2):127–37.

    Article  CAS  PubMed  Google Scholar 

  77. Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res. 2011;4(7):1021–9. doi:10.1158/1940-6207.CAPR-11-0110.

    Article  CAS  Google Scholar 

  78. Dankner R, Shanik MH, Keinan-Boker L, Cohen C, Chetrit A. Effect of elevated basal insulin on cancer incidence and mortality in cancer incident patients: the Israel GOH 29-year follow-up study. Diabetes Care. 2012;35(7):1538–43. doi:10.2337/dc11-1513.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clinical Oncol. 2002;20(1):42–51.

    Article  CAS  Google Scholar 

  80. Stocks T, Lukanova A, Rinaldi S, Biessy C, Dossus L, Lindahl B, et al. Insulin resistance is inversely related to prostate cancer: a prospective study in Northern Sweden. Int J Cancer. 2007;120(12):2678–86. doi:10.1002/ijc.22587.

    Article  CAS  PubMed  Google Scholar 

  81. Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab. 2000;278(6):E967–76.

    CAS  PubMed  Google Scholar 

  82. Brismar K, Fernqvist-Forbes E, Wahren J, Hall K. Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-3, and IGF-I in insulin-dependent diabetes. J Clin Endocrinol Metab. 1994;79(3):872–8. doi:10.1210/jcem.79.3.7521354.

    CAS  PubMed  Google Scholar 

  83. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW et al. Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med. 2011;3(70):70ra13. doi:10.1126/scitranslmed.3001845.

    Google Scholar 

  84. Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer. 2006;13(2):583–92. doi:10.1677/erc.1.01149.

    Article  CAS  PubMed  Google Scholar 

  85. Cao Y, Nimptsch K, Shui IM, Platz EA, Wu K, Pollak MN, et al. Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer. Int J Cancer. 2015;136(10):2418–26. doi:10.1002/ijc.29295.

    Article  CAS  PubMed  Google Scholar 

  86. Crowe FL, Key TJ, Allen NE, Appleby PN, Overvad K, Gronbaek H, et al. A cross-sectional analysis of the associations between adult height, BMI and serum concentrations of IGF-I and IGFBP-1 -2 and −3 in the European Prospective Investigation into Cancer and Nutrition (EPIC). Ann Hum Biol. 2011;38(2):194–202. doi:10.3109/03014460.2010.507221.

    Article  PubMed  Google Scholar 

  87. Galli G, Pinchera A, Piaggi P, Fierabracci P, Giannetti M, Querci G, et al. Serum insulin-like growth factor-1 concentrations are reduced in severely obese women and raise after weight loss induced by laparoscopic adjustable gastric banding. Obes Surg. 2012;22(8):1276–80. doi:10.1007/s11695-012-0669-1.

    Article  PubMed  Google Scholar 

  88. Novosyadlyy R, LeRoith D. Hyperinsulinemia and type 2 diabetes: impact on cancer. Cell Cycle. 2010;9(8):1449–50.

    Article  CAS  PubMed  Google Scholar 

  89. Ferguson RD, Gallagher EJ, Cohen D, Tobin-Hess A, Alikhani N, Novosyadlyy R, et al. Hyperinsulinemia promotes metastasis to the lung in a mouse model of Her2-mediated breast cancer. Endocr Relat Cancer. 2013;20(3):391–401. doi:10.1530/ERC-12-0333.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Fierz Y, Novosyadlyy R, Vijayakumar A, Yakar S, LeRoith D. Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. Diabetes. 2010;59(3):686–93. doi:10.2337/db09-1291.

    Article  CAS  PubMed  Google Scholar 

  91. Bol DK, Kiguchi K, Gimenez-Conti I, Rupp T, DiGiovanni J. Overexpression of insulin-like growth factor-1 induces hyperplasia, dermal abnormalities, and spontaneous tumor formation in transgenic mice. Oncogene. 1997;14(14):1725–34. doi:10.1038/sj.onc.1201011.

    Article  CAS  PubMed  Google Scholar 

  92. Pollak M, Blouin MJ, Zhang JC, Kopchick JJ. Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. Br J Cancer. 2001;85(3):428–30. doi:10.1054/bjoc.2001.1895.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Gallagher EJ, Alikhani N, Tobin-Hess A, Blank J, Buffin NJ, Zelenko Z, et al. Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-I receptor. Diabetes. 2013;62(10):3553–60. doi:10.2337/db13-0249.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. Cancer Res. 2002;62(4):1030–5.

    CAS  PubMed  Google Scholar 

  95. Dunn SE, Kari FW, French J, Leininger JR, Travlos G, Wilson R, et al. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. Cancer Res. 1997;57(21):4667–72.

    CAS  PubMed  Google Scholar 

  96. Wu Y, Cui K, Miyoshi K, Hennighausen L, Green JE, Setser J, et al. Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res. 2003;63(15):4384–8.

    CAS  PubMed  Google Scholar 

  97. De Meyts P, Palsgaard J, Sajid W, Theede AM, Aladdin H. Structural biology of insulin and IGF-1 receptors. Novartis Found Symp. 2004;262:160–71. discussion 71–6, 265–8.

    Article  PubMed  Google Scholar 

  98. LeRoith D, Werner H, Beitner-Johnson D, Roberts Jr CT. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev. 1995;16(2):143–63. doi:10.1210/edrv-16-2-143.

    Article  CAS  PubMed  Google Scholar 

  99. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev. 2009;30(6):586–623. doi:10.1210/er.2008-0047.

    Article  CAS  PubMed  Google Scholar 

  100. Harrington SC, Weroha SJ, Reynolds C, Suman VJ, Lingle WL, Haluska P. Quantifying insulin receptor isoform expression in FFPE breast tumors. Growth Horm IGF Res. 2012;22(3–4):108–15. doi:10.1016/j.ghir.2012.04.001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Yakar S, Leroith D, Brodt P. The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: lessons from animal models. Cytokine Growth Factor Rev. 2005;16(4–5):407–20. doi:10.1016/j.cytogfr.2005.01.010.

    Article  CAS  PubMed  Google Scholar 

  102. Webster NJ, Resnik JL, Reichart DB, Strauss B, Haas M, Seely BL. Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer. Cancer Res. 1996;56(12):2781–8.

    CAS  PubMed  Google Scholar 

  103. Frittitta L, Cerrato A, Sacco MG, Weidner N, Goldfine ID, Vigneri R. The insulin receptor content is increased in breast cancers initiated by three different oncogenes in transgenic mice. Breast Cancer Res Treat. 1997;45(2):141–7.

    Article  CAS  PubMed  Google Scholar 

  104. King H, Aleksic T, Haluska P, Macaulay VM. Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treat Rev. 2014;40(9):1096–105. doi:10.1016/j.ctrv.2014.07.004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  105. Ulanet DB, Ludwig DL, Kahn CR, Hanahan D. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci U S A. 2010;107(24):10791–8. doi:10.1073/pnas.0914076107.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330(7503):1304–5. doi:10.1136/bmj.38415.708634.F7.

    Article  PubMed  PubMed Central  Google Scholar 

  107. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108(8):1167–74. doi:10.1172/JCI13505.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Kim SY, Kang JW, Song X, Kim BK, Yoo YD, Kwon YT, et al. Role of the IL-6-JAK1-STAT3-Oct-4 pathway in the conversion of non-stem cancer cells into cancer stem-like cells. Cell Signal. 2013;25(4):961–9. doi:10.1016/j.cellsig.2013.01.007.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  109. Jeong SH, Lee YJ, Cho BI, Ha WS, Choi SK, Jung EJ, et al. OCT-1 overexpression is associated with poor prognosis in patients with well-differentiated gastric cancer. Tumour Biol. 2014;35(6):5501–9. doi:10.1007/s13277-014-1724-4.

    Article  CAS  PubMed  Google Scholar 

  110. Advani AS, Lim K, Gibson S, Shadman M, Jin T, Copelan E, et al. OCT-2 expression and OCT-2/BOB.1 co-expression predict prognosis in patients with newly diagnosed acute myeloid leukemia. Leuk Lymphoma. 2010;51(4):606–12. doi:10.3109/10428191003592735.

    Article  CAS  PubMed  Google Scholar 

  111. El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000;275(1):223–8.

    Article  CAS  PubMed  Google Scholar 

  112. Levine AJ, Feng Z, Mak TW, You H, Jin S. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev. 2006;20(3):267–75. doi:10.1101/gad.1363206.

    Article  CAS  PubMed  Google Scholar 

  113. Adekola K, Rosen ST, Shanmugam M. Glucose transporters in cancer metabolism. Curr Opin Oncol. 2012;24(6):650–4. doi:10.1097/CCO.0b013e328356da72.

    Article  CAS  PubMed  Google Scholar 

  114. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005;202(3):654–62. doi:10.1002/jcp.20166.

    Article  CAS  PubMed  Google Scholar 

  115. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–33. doi:10.1126/science.1160809.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  116. Scafoglio C, Hirayama BA, Kepe V, Liu J, Ghezzi C, Satyamurthy N, et al. Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci U S A. 2015;112(30):E4111–9. doi:10.1073/pnas.1511698112.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. de Beer JC, Liebenberg L. Does cancer risk increase with HbA1c, independent of diabetes? Br J Cancer. 2014;110(9):2361–8. doi:10.1038/bjc.2014.150.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  118. Bell Jr RH, McCullough PJ, Pour PM. Influence of diabetes on susceptibility to experimental pancreatic cancer. Am J Surg. 1988;155(1):159–64.

    Article  PubMed  Google Scholar 

  119. Cocca C, Martin G, Rivera E, Davio C, Cricco G, Lemos B, et al. An experimental model of diabetes and cancer in rats. Eur J Cancer. 1998;34(6):889–94.

    Article  CAS  PubMed  Google Scholar 

  120. Shafie SM, Grantham FH. Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice. J Natl Cancer Inst. 1981;67(1):51–6.

    CAS  PubMed  Google Scholar 

  121. Barbosa-Desongles A, Hernandez C, De Torres I, Munell F, Poupon MF, Simo R, et al. Diabetes protects from prostate cancer by downregulating androgen receptor: new insights from LNCaP cells and PAC120 mouse model. PLoS One. 2013;8(9), e74179. doi:10.1371/journal.pone.0074179.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Chahil TJ, Ginsberg HN. Diabetic dyslipidemia. Endocrinol Metab Clin North Am. 2006;35(3):491–510. doi:10.1016/j.ecl.2006.06.002. vii-viii.

    Article  CAS  PubMed  Google Scholar 

  123. Nelson ER, Chang CY, McDonnell DP. Cholesterol and breast cancer pathophysiology. Trends Endocrinol Metab. 2014;25(12):649–55. doi:10.1016/j.tem.2014.10.001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  124. Mainous 3rd AG, Wells BJ, Koopman RJ, Everett CJ, Gill JM. Iron, lipids, and risk of cancer in the Framingham Offspring cohort. Am J Epidemiol. 2005;161(12):1115–22. doi:10.1093/aje/kwi131.

    Article  PubMed  Google Scholar 

  125. Melvin JC, Holmberg L, Rohrmann S, Loda M, Van Hemelrijck M. Serum lipid profiles and cancer risk in the context of obesity: four meta-analyses. J Cancer Epidemiol. 2013;2013:823849. doi:10.1155/2013/823849.

    PubMed  PubMed Central  Google Scholar 

  126. Hsu MC, Lee KT, Hsiao WC, Wu CH, Sun HY, Lin IL, et al. The dyslipidemia-associated SNP on the APOA1/C3/A5 gene cluster predicts post-surgery poor outcome in Taiwanese breast cancer patients: a 10-year follow-up study. BMC Cancer. 2013;13:330. doi:10.1186/1471-2407-13-330.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  127. Chang NW, Chen DR, Wu CT, Aouizerat BE, Chen FN, Hung SJ, et al. Influences of apolipoprotein E polymorphism on the risk for breast cancer and HER2/neu status in Taiwan. Breast Cancer Res Treat. 2005;90(3):257–61. doi:10.1007/s10549-004-4656-7.

    Article  CAS  PubMed  Google Scholar 

  128. Moysich KB, Freudenheim JL, Baker JA, Ambrosone CB, Bowman ED, Schisterman EF, et al. Apolipoprotein E genetic polymorphism, serum lipoproteins, and breast cancer risk. Mol Carcinog. 2000;27(1):2–9. doi:10.1002/(SICI)1098-2744(200001)27:1<2::AID-MC2>3.0.CO;2-W [pii].

    Article  CAS  PubMed  Google Scholar 

  129. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med. 2012;367(19):1792–802. doi:10.1056/NEJMoa1201735.

    Article  CAS  PubMed  Google Scholar 

  130. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology. 2013;144(2):323–32. doi:10.1053/j.gastro.2012.10.005.

    Article  CAS  PubMed  Google Scholar 

  131. Yu O, Eberg M, Benayoun S, Aprikian A, Batist G, Suissa S, et al. Use of statins and the risk of death in patients with prostate cancer. J Clin Oncol. 2014;32(1):5–11. doi:10.1200/JCO.2013.49.4757.

    Article  PubMed  CAS  Google Scholar 

  132. Ahern TP, Pedersen L, Tarp M, Cronin-Fenton DP, Garne JP, Silliman RA, et al. Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study. J Natl Cancer Inst. 2011;103(19):1461–8. doi:10.1093/jnci/djr291.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Zhang XL, Liu M, Qian J, Zheng JH, Zhang XP, Guo CC, et al. Statin use and risk of kidney cancer: a meta-analysis of observational studies and randomized trials. Br J Clin Pharmacol. 2014;77(3):458–65. doi:10.1111/bcp.12210.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Tan M, Song X, Zhang G, Peng A, Li X, Li M, et al. Statins and the risk of lung cancer: a meta-analysis. PLoS One. 2013;8(2), e57349. doi:10.1371/journal.pone.0057349.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Zhang XL, Geng J, Zhang XP, Peng B, Che JP, Yan Y, et al. Statin use and risk of bladder cancer: a meta-analysis. Cancer Causes Control. 2013;24(4):769–76. doi:10.1007/s10552-013-0159-3.

    Article  PubMed  Google Scholar 

  136. Cui X, Xie Y, Chen M, Li J, Liao X, Shen J, et al. Statin use and risk of pancreatic cancer: a meta-analysis. Cancer Causes Control. 2012;23(7):1099–111. doi:10.1007/s10552-012-9979-9.

    Article  PubMed  Google Scholar 

  137. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet. 1997;32(5):403–25. doi:10.2165/00003088-199732050-00005.

    Article  CAS  PubMed  Google Scholar 

  138. Woditschka S, Habel LA, Udaltsova N, Friedman GD, Sieh W. Lipophilic statin use and risk of breast cancer subtypes. Cancer Epidemiol Biomarkers Prev. 2010;19(10):2479–87. doi:10.1158/1055-9965.EPI-10-0524.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Dansky HM, Shu P, Donavan M, Montagno J, Nagle DL, Smutko JS, et al. A phenotype-sensitizing Apoe-deficient genetic background reveals novel atherosclerosis predisposition loci in the mouse. Genetics. 2002;160(4):1599–608.

    CAS  PubMed  PubMed Central  Google Scholar 

  140. Alikhani N, Ferguson RD, Novosyadlyy R, Gallagher EJ, Scheinman EJ, Yakar S, et al. Mammary tumor growth and pulmonary metastasis are enhanced in a hyperlipidemic mouse model. Oncogene. 2013;32(8):961–7. doi:10.1038/onc.2012.113.

    Article  CAS  PubMed  Google Scholar 

  141. Llaverias G, Danilo C, Mercier I, Daumer K, Capozza F, Williams TM, et al. Role of cholesterol in the development and progression of breast cancer. Am J Pathol. 2011;178(1):402–12. doi:10.1016/j.ajpath.2010.11.005.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  142. Llaverias G, Danilo C, Wang Y, Witkiewicz AK, Daumer K, Lisanti MP, et al. A Western-type diet accelerates tumor progression in an autochthonous mouse model of prostate cancer. Am J Pathol. 2010;177(6):3180–91. doi:10.2353/ajpath.2010.100568.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013;342(6162):1094–8. doi:10.1126/science.1241908.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  144. Pelton K, Coticchia CM, Curatolo AS, Schaffner CP, Zurakowski D, Solomon KR, et al. Hypercholesterolemia induces angiogenesis and accelerates growth of breast tumors in vivo. Am J Pathol. 2014;184(7):2099–110. doi:10.1016/j.ajpath.2014.03.006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  145. Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR. Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res. 2002;62(8):2227–31.

    CAS  PubMed  Google Scholar 

  146. Scheinman EJ, Rostoker R, Leroith D. Cholesterol affects gene expression of the Jun family in colon carcinoma cells using different signaling pathways. Mol Cell Endocrinol. 2013;374(1–2):101–7. doi:10.1016/j.mce.2013.04.011.

    Article  CAS  PubMed  Google Scholar 

  147. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447–54. doi:10.1158/0008-5472.CAN-08-0249.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  148. Pelton K, Freeman MR, Solomon KR. Cholesterol and prostate cancer. Curr Opin Pharmacol. 2012;12(6):751–9. doi:10.1016/j.coph.2012.07.006.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  149. de Medina P, Paillasse MR, Segala G, Voisin M, Mhamdi L, Dalenc F, et al. Dendrogenin A arises from cholesterol and histamine metabolism and shows cell differentiation and anti-tumour properties. Nat Commun. 2013;4:1840. doi:10.1038/ncomms2835.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  150. Harford KA, Reynolds CM, McGillicuddy FC, Roche HM. Fats, inflammation and insulin resistance: insights to the role of macrophage and T-cell accumulation in adipose tissue. Proc Nutr Soc. 2011;70(4):408–17. doi:10.1017/S0029665111000565.

    Article  CAS  PubMed  Google Scholar 

  151. Marette A. Mediators of cytokine-induced insulin resistance in obesity and other inflammatory settings. Curr Opin Clin Nutr Metab Care. 2002;5(4):377–83.

    Article  CAS  PubMed  Google Scholar 

  152. Onuma M, Bub JD, Rummel TL, Iwamoto Y. Prostate cancer cell-adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem. 2003;278(43):42660–7. doi:10.1074/jbc.M304984200.

    Article  CAS  PubMed  Google Scholar 

  153. Rose DP, Komninou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev. 2004;5(3):153–65. doi:10.1111/j.1467-789X.2004.00142.x.

    Article  CAS  PubMed  Google Scholar 

  154. Gonullu G, Ersoy C, Ersoy A, Evrensel T, Basturk B, Kurt E, et al. Relation between insulin resistance and serum concentrations of IL-6 and TNF-alpha in overweight or obese women with early stage breast cancer. Cytokine. 2005;31(4):264–9. doi:10.1016/j.cyto.2005.05.003.

    Article  CAS  PubMed  Google Scholar 

  155. Rosean TR, Tompkins VS, Tricot G, Holman CJ, Olivier AK, Zhan F, et al. Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. Immunol Res. 2014;59(1–3):188–202. doi:10.1007/s12026-014-8528-x.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  156. Cozen W, Gebregziabher M, Conti DV, Van Den Berg DJ, Coetzee GA, Wang SS, et al. Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2285–91. doi:10.1158/1055-9965.EPI-06-0446.

    Article  CAS  PubMed  Google Scholar 

  157. Plaisance I, Morandi C, Murigande C, Brink M. TNF-alpha increases protein content in C2C12 and primary myotubes by enhancing protein translation via the TNF-R1, PI3K, and MEK. Am J Physiol Endocrinol Metab. 2008;294(2):E241–50. doi:10.1152/ajpendo.00129.2007.

    Article  CAS  PubMed  Google Scholar 

  158. Zinman B, Hanley AJ, Harris SB, Kwan J, Fantus IG. Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab. 1999;84(1):272–8. doi:10.1210/jcem.84.1.5405.

    CAS  PubMed  Google Scholar 

  159. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature. 1997;389(6651):610–4. doi:10.1038/39335.

    Article  CAS  PubMed  Google Scholar 

  160. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425–32. doi:10.1038/372425a0.

    Article  CAS  PubMed  Google Scholar 

  161. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med. 1999;341(12):879–84. doi:10.1056/NEJM199909163411204.

    Article  CAS  PubMed  Google Scholar 

  162. Maffei M, Fei H, Lee GH, Dani C, Leroy P, Zhang Y, et al. Increased expression in adipocytes of ob RNA in mice with lesions of the hypothalamus and with mutations at the db locus. Proc Natl Acad Sci U S A. 1995;92(15):6957–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  163. Vona-Davis L, Howard-McNatt M, Rose DP. Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev. 2007;8(5):395–408. doi:10.1111/j.1467-789X.2007.00396.x.

    Article  CAS  PubMed  Google Scholar 

  164. Surmacz E. Leptin and adiponectin: emerging therapeutic targets in breast cancer. J Mammary Gland Biol Neoplasia. 2013;18(3–4):321–32. doi:10.1007/s10911-013-9302-8.

    Article  PubMed  Google Scholar 

  165. Hardwick JC, Van Den Brink GR, Offerhaus GJ, Van Deventer SJ, Peppelenbosch MP. Leptin is a growth factor for colonic epithelial cells. Gastroenterology. 2001;121(1):79–90.

    Article  CAS  PubMed  Google Scholar 

  166. Khan S, Shukla S, Sinha S, Meeran SM. Role of adipokines and cytokines in obesity-associated breast cancer: therapeutic targets. Cytokine Growth Factor Rev. 2013;24(6):503–13. doi:10.1016/j.cytogfr.2013.10.001.

    Article  CAS  PubMed  Google Scholar 

  167. Vansaun MN. Molecular pathways: adiponectin and leptin signaling in cancer. Clin Cancer Res. 2013;19(8):1926–32. doi:10.1158/1078-0432.CCR-12-0930.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  168. Ishikawa M, Kitayama J, Yamauchi T, Kadowaki T, Maki T, Miyato H, et al. Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. Cancer Sci. 2007;98(7):1120–7. doi:10.1111/j.1349-7006.2007.00486.x.

    Article  CAS  PubMed  Google Scholar 

  169. Hebbard L, Ranscht B. Multifaceted roles of adiponectin in cancer. Best Pract Res Clin Endocrinol Metab. 2014;28(1):59–69. doi:10.1016/j.beem.2013.11.005.

    Article  CAS  PubMed  Google Scholar 

  170. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, et al. The hormone resistin links obesity to diabetes. Nature. 2001;409(6818):307–12. doi:10.1038/35053000.

    Article  CAS  PubMed  Google Scholar 

  171. Zhang J, Wu Y, Zhang Y, Leroith D, Bernlohr DA, Chen X. The role of lipocalin 2 in the regulation of inflammation in adipocytes and macrophages. Mol Endocrinol. 2008;22(6):1416–26. doi:10.1210/me.2007-0420.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  172. Hursting SD, Nunez NP, Varticovski L, Vinson C. The obesity-cancer link: lessons learned from a fatless mouse. Cancer Res. 2007;67(6):2391–3. doi:10.1158/0008-5472.CAN-06-4237.

    Article  CAS  PubMed  Google Scholar 

  173. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003;95(16):1218–26.

    Article  CAS  PubMed  Google Scholar 

  174. Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1531–43.

    CAS  PubMed  Google Scholar 

  175. Slattery ML, Potter JD, Curtin K, Edwards S, Ma KN, Anderson K, et al. Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Cancer Res. 2001;61(1):126–30.

    CAS  PubMed  Google Scholar 

  176. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst. 1996;88(16):1118–26.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Diabetes & Bone Disease, Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA

    Emily J. Gallagher, Brian A. Neel, Irini M. Antoniou, Shoshana Yakar & Derek LeRoith

Authors
  1. Emily J. Gallagher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brian A. Neel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Irini M. Antoniou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shoshana Yakar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Derek LeRoith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emily J. Gallagher .

Editor information

Editors and Affiliations

  1. Lenox Hill Hospital Division of Endocrinology, New York, New York, USA

    Leonid Poretsky

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this entry

Cite this entry

Gallagher, E.J., Neel, B.A., Antoniou, I.M., Yakar, S., LeRoith, D. (2017). The Increased Risk of Cancer in Obesity and Type 2 Diabetes: Potential Mechanisms. In: Poretsky, L. (eds) Principles of Diabetes Mellitus. Springer, Cham. https://doi.org/10.1007/978-3-319-20797-1_36-2

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-20797-1_36-2

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-20797-1

  • Online ISBN: 978-3-319-20797-1

  • eBook Packages: Springer Reference MedicineReference Module Medicine

Publish with us

Policies and ethics

Chapter history

  1. Latest

    The Increased Risk of Cancer in Obesity and Type 2 Diabetes: Potential Mechanisms
    Published:
    10 February 2017

    DOI: https://doi.org/10.1007/978-3-319-20797-1_36-2

  2. Original

    The Increased Risk of Cancer in Obesity and Type 2 Diabetes: Potential Mechanisms
    Published:
    01 March 2016

    DOI: https://doi.org/10.1007/978-3-319-20797-1_36-1

Search

Navigation